| Literature DB >> 35922806 |
Anna Mîra1, Pablo Lamata1, Kuberan Pushparajah1,2, Georgina Abraham1, Charlène A Mauger3, Andrew D McCulloch4,5, Jeffrey H Omens4,5, Malenka M Bissell6, Zach Blair7, Tyler Huffaker7, Animesh Tandon7,8, Sandy Engelhardt9,10, Sven Koehler9,10, Thomas Pickardt11, Philipp Beerbaum11,12, Samir Sarikouch11,13, Heiner Latus14, Gerald Greil7, Alistair A Young15,16, Tarique Hussain7.
Abstract
BACKGROUND: Maladaptive remodelling mechanisms occur in patients with repaired tetralogy of Fallot (rToF) resulting in a cycle of metabolic and structural changes. Biventricular shape analysis may indicate mechanisms associated with adverse events independent of pulmonary regurgitant volume index (PRVI). We aimed to determine novel remodelling patterns associated with adverse events in patients with rToF using shape and function analysis.Entities:
Keywords: Biomarker; Biventricular shape; Magnetic resonance imaging; Tetralogy of Fallot
Mesh:
Year: 2022 PMID: 35922806 PMCID: PMC9351245 DOI: 10.1186/s12968-022-00877-x
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 6.903
Patient demographics
| All patients (n = 192) | Adverse outcomes (n = 16) | No adverse outcome (n = 176) | |
|---|---|---|---|
| Gender [F (%)] | 77 (40) | (5) 31 | 72 (41) |
| Height [cm] | 163.3 ± 14.7 | 164.2 ± 12.3 | 163.2 ± 14.9 |
| Weight [kg] | 57.0 ± 18.9 | 55.0 ± 18.4 | 57.2 ± 19.0 |
| BSA [m2] | 1.59 ± 0.3 | 1.57 ± 0.3 | 1.6 ± 0.3 |
| Median age at baseline exam [years](IQR) | 15 (6.3) | 16.5 (9.3) | 15 (6) |
| Median age at ToF repair [years](IQR) | 1 (3) | 1 (1) | 1 (3) |
| Median time from ToF repair to baseline exam [years] (IQR) | 13.5 (5) | 15 (6) | 13 (5) |
| Median number of RCS before baseline exam [years] | 0 (1) | 1(1) | 0 (1)* |
| PVR after baseline exam BE [# (%)] | 27 (14) | 2 (12) † | 25 (14) |
| Diagnosis [# (%)] | |||
| ToF | 161 (84) | 14 (87) | 147 (83) |
| Pulmonary atresia and VSD | 27 (14) | 2 (13) | 25 (14) |
| DORV | 4 (2) | 0 (0) | 4 (2) |
| Type of TOF repair [# (%)] | |||
| Transannular patch | 44 (23) | 5 (31) | 39 (23) |
| Transannular patch with MPA patch | 40 (21) | 3 (19) | 37 (22) |
| No patch | 62(32) | 4 (24) | 58 (33) |
| RV to PA conduit | 23 (12) | 2 (13) | 21 (12) |
| Not defined | 23 (12) | 2 (13) | 21 (12) |
| NYHA class [# (%)] | |||
| I–II | 188 (98) | 192 (100) | 172 (98) |
| III | 4 (2) | 0 (0) | 4 (2) |
| Exercise parameters at baseline exam | |||
| Peak heart rate | 169 ± 20 | 160 ± 29 | 170 ± 19 |
| Peak VO2 (mL VO2/kg/min)‡ | 31.8 ± 8.9 | 28.3 ± 10.8 | 32.1 ± 8.6 |
Normal distributed measurements are given in the format of mean ± std dev, p-values are computed using Welch's test. Non-normal distributed measurements are given in the format of median (IQR) and p-values are computed using Mood’s Median test. P-value annotation legend: *:0.01 < p < = 0.05; †One patient had PVR before baseline exam. Data were available for 188 patients
BSA body surface area, PVR pulmonary valve replacement, DORV Double outlet right ventricle, MPA main pulmonary artery, NYHA New York Heart Association, PA pulmonary artery, PVR pulmonic valve replacement, RCS redo corrective surgery, RV Right ventricular, ToF tetralogy of Fallot, VSD ventricular septal defect
Fig. 1Patient-specific biventricular shape modelling. Left—short axis contours, middle—long axis contours, right: biventricular shape. Contours: green—left ventricular (LV) epicardium, red—LV endocardium, yellow—right ventricle (RV) endocardium, orange—left atrium, cyan—right atrium. Surfaces: (right) green—RV, purple—LV
Fig. 2Volume parcellation. The right ventricle (RV) mesh is cropped according to the landmarks’ closest distance (PV—pulmonary valve, TV—tricuspid valve, A—RV apex). Cyan—inlet volume, green—outlet volume, and purple—apical volume
Fig. 3Definition of calliper distances. Yellow—left ventricle (LV). Blue—right ventricle (RV). HRV—the distance between tricuspid valve (TV) centroid and RV apex. HLV—the distance between the mitral valve (MV) centroid and RV apex. WRV—the distance between the RV free wall and the septum measured at mid RV height (r*HRV, r = ½) on the axis perpendicular to the septum. WLV—the distance between the LV endocardium and the septum measured at mid-LV height (r*HLV, r = ½) along the axis perpendicular to the septum. LRV—the distance between the two most distant points on the RV free wall at mid RV height (½*HLV) along the axis parallel to the septum
Volumetric and functional measurements
| All patients (n = 192) | Adverse outcome (n = 16) | No adverse outcome (n = 176) | |
|---|---|---|---|
| DBP [mmHg] | 64.1 ± 10.2 | 65.0 ± 11.3 | 64.0 ± 10.1 |
| SBP [mmHg] | 118.0 ± 14.4 | 117.4 ± 15.5 | 118.0 ± 14.3 |
| QRS duration (ms) | 147.2 ± 22.8 | 145.1 ± 30.6 | 147.4 ± 21.9 |
| LVEDVI [ml/m2] | 88.1 ± 18.2 | 101.3 ± 31.5 | 86.9 ± 15.8 |
| LVESVI [ml/m2] | 42.9 ± 14.8 | 53.5 ± 30.9 | 42.0 ± 12.1 |
| LV SVI [ml/m2] | 45.3 ± 9.1 | 47.7 ± 10.2 | 45.0 ± 8.9 |
| LVEF [%] | 52 ± 8 | 49 ± 10 | 52 ± 8 |
| RVEDVI [ml/m2] | 131.4 ± 33.3 | 138.4 ± 31.7 | 130.7 ± 33.3 |
| RVESVI [ml/m2] | 83.7 ± 25.7 | 94.7 ± 26.2 | 82.8 ± 25.5 |
| RV SVI [ml/m2] | 47.7 ± 15.2 | 43.9 ± 14.8 | 48.0 ± 15.2 |
| RVEF [%] | 37 ± 9 | 32 ± 9 | 37 ± 9* |
| LVMI [g/m2] | 67.6 ± 12.2 | 77.0 ± 18.0 | 66.7 ± 11.0* |
| LV ED MVR [g/ml] | 0.77 ± 0.12 | 0.78 ± 0.1 | 0.78 ± 0.12 |
| LV ES MVR [g/ml] | 1.40 ± 0.28 | 1.38 ± 0.33 | 1.41 ± 0.27 |
The values are given in the format of mean ± std. DPB diastolic blood pressure, ED end-diastole, LVMI left ventricular mass index, EDVI end-diastolic volume index, EF ejection fraction, ES end-systole, ESVI end-systole volume index. LV left ventricle, MVR mass to volume ratio, RV right ventricle, SPB systolic blood pressure, SV stroke volume. *p < 0.05 no adverse outcomes vs adverse outcomes
Partial volumes and partial functional measurements
| All patients (n = 192) | Adverse outcome (n = 16) | No adverse outcome (n = 176) | |
|---|---|---|---|
| RV ED IPVI [ml/m2] | 59.3 ± 15.7 | 64.7 ± 13.0 | 58.7 ± 15.7 |
| RV ES IPVI [ml/m2] | 36.9 ± 12.2 | 42.9 ± 10.9 | 36.5 ± 12.6* |
| RV ED OPVI [ml/m2] | 25.7 ± 10.0 | 25.0 ± 10.6 | 25.7 ± 9.9 |
| RV ES OPVI [ml/m2] | 18.2 ± 7.4 | 18.6 ± 8.6 | 18.1 ± 7.3 |
| RV ED APVI [ml/m2] | 46.3 ± 12.5 | 48.7 ± 11.3 | 46.1 ± 12.6 |
| RV ES APVI [ml/m2] | 28.6 ± 8.9 | 33.0 ± 8.4 | 28.3 ± 9.0* |
| RV IPSVI [ml/m2] | 22.4 ± 7.2 | 21.8 ± 5.5 | 22.2 ± 7.8 |
| RV OPSVI [ml/m2] | 7.5 ± 5.0 | 6.4 ± 5.2 | 7.6 ± 5.1 |
| RV APSVI [ml/m2] | 17.7 ± 6.5 | 15.7 ± 6.3 | 17.8 ± 6.5 |
| RV IPEF [%] | 38 ± 9 | 34 ± 7 | 38 ± 9* |
| RV OPEF [%] | 28 ± 15 | 24 ± 16 | 28 ± 16 |
| RV APEF [%] | 38 ± 10 | 32 ± 11 | 39 ± 10* |
The values are presented in the format of mean ± s.d. A apical region, I Inflow, O outflow, PEF partial ejection fraction, PSVI partial stroke volume index, PVI partial volume index. *p < 0.05 no adverse outcomes vs adverse outcomes
Fig. 4TOP: Association between geometrical features and the shape modes (SM): a SM6, b SM8. BOTTOM: Box-plots—score distribution of SM6 (a), SM8 (b) across the studied population for adverse outcomes (AO) and no adverse outcomes (NAO). The box denotes Q1 and Q3, whiskers Q1-1.5*IQR and Q3 + 1.5*IQR and diamonds are outliers. ED end-diastole, ES end-systole, LV left ventricle, RV right ventricle
Fig. 5Shape pattern associated with adverse events a and pulmonary regurgitation (b). Low risk: shape associated with no adverse outcomes. High risk: shape associated with adverse outcomes. Low pulmonary regurgitation: shape associated with reduced pulmonary regurgitation. High P: shape associated with high pulmonary regurgitation. Green and blue surfaces show LV and RV (respectively) at ES. Wireframe: LV and RV at ED. Red arrow: RV basal remodelling; purple—LV basal remodelling; orange—RV apical remodelling and LV apical displacement; blue—RV apical dilatation. Yellow circles illustrate the contrast between circular shape versus elliptical shape. Box plots: a Distribution of the risk score for adverse outcomes and no adverse outcomes, b) distribution of PR score for adverse outcomes and no adverse outcomes. The box denotes Q1 and Q3, whiskers Q1-1.5*IQR and Q3 + 1.5*IQR and diamonds are outliers. Red lines: + 2std and −2std representing the score of the plotted shapes
Fig. 6Association between pulmonary regurgitation and LDA risk score (SM6 + APEF), RVEF, and apical ejection fraction (APEF). Subjects with adverse events are marked in yellow circles